A Phase 1 Dose-Escalation Study of LY2495655, an Anti-Myostatin Monoclonal Antibody, in Patients With Advanced Cancer

Trial Profile

A Phase 1 Dose-Escalation Study of LY2495655, an Anti-Myostatin Monoclonal Antibody, in Patients With Advanced Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2016

At a glance

  • Drugs Landogrozumab (Primary)
  • Indications Breast cancer; Cancer; Prostate cancer
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 08 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 19 Oct 2015 Planned End Date changed from 1 Jul 2015 to 1 Jan 2016 as per ClinicalTrials.gov record.
    • 05 Jun 2015 Planned End Date changed from 1 Jan 2014 to 1 Jul 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top